Seizures Late in Life May be an Early Sign of Alzheimer Disease
EMBARGOED FOR RELEASE: 3 P.M. (CT), MONDAY, JULY 8, 2013
Media Advisory: To contact author Keith A. Vossel. M.D., M. Sc., call Anne D. Holden at 415-734-2534 or email Anne.Holden@gladstone.ucsf.edu.
CHICAGO – Patients with epilepsy who had amnestic mild cognitive impairment (aMCI) or Alzheimer disease (AD) presented earlier with cognitive decline than patients who did not have epilepsy, according to a report published by JAMA Neurology, a JAMA Network publication.
AD increases a patient’s risk of risk of seizures, and patients with AD and seizure disorders have greater cognitive impairment, more rapid progression of symptoms and more severe neuronal loss at autopsy than those without seizures, according to the study background.
“Epileptic activity associated with Alzheimer disease (AD) deserves increased attention because it has a harmful impact on these patients, can easily go unrecognized and untreated and may reflect pathogenic processes that also contribute to other aspects of the illness,” authors note in the study by Keith A. Vossel, M.D., M.Sc., of the Gladstone Institute of Neurological Disease, San Francisco, Calif., and colleagues.
The study included 54 patients with a diagnosis of aMCI plus epilepsy (n=12), AD plus epilepsy (n=35) and AD plus subclinical epileptiform activity (n=7).
Patients with aMCI who had epilepsy presented with symptoms of cognitive decline 6.8 years earlier than patients with aMCI who did not have epilepsy (64.3 vs. 71.1 years). Patients with AD who had epilepsy presented with cognitive decline 5.5 years earlier than patients with AD who did not have epilepsy (64.8 vs. 70.3 years), according to the results.
“Careful identification and treatment of epilepsy in such patients may improve their clinical course,” the study concludes.
(JAMA Neurol. Published online July 8, 2013. doi:10.1001/jamaneurol.2013.136. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor’s Note: Authors made conflict of interest disclosures. This study was supported by National Institutes of Health grants and other sources. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding andsupport, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.